Comparing Two Treatments for Advanced Colorectal Cancer
Author Information
Author(s): Feliu J, Castañón C, Salud A, Mel J R, Escudero P, Pelegrín A, López-Gómez L, Ruiz M, González E, Juárez F, Lizón J, Castro J, González-Barón M
Primary Institution: Service of Medical Oncology, La Paz, Madrid, Spain
Hypothesis
Which of the two chemotherapy regimens, raltitrexed-oxaliplatin or raltitrexed-irinotecan, offers better activity and less toxicity in advanced colorectal cancer?
Conclusion
Both chemotherapy regimens have high efficacy and similar toxicity levels in treating advanced colorectal cancer.
Supporting Evidence
- Overall response rate was 46% for raltitrexed-oxaliplatin and 34% for raltitrexed-irinotecan.
- 69% of patients in the raltitrexed-oxaliplatin group were still alive after 14 months.
- Both regimens showed similar toxicity profiles, with no significant differences in severe side effects.
Takeaway
Doctors wanted to see which of two treatments for colon cancer worked better and caused fewer side effects. They found both treatments were good.
Methodology
Patients were randomly assigned to receive either raltitrexed-oxaliplatin or raltitrexed-irinotecan and were monitored for response and toxicity.
Potential Biases
Potential bias due to the non-blinded nature of the trial.
Limitations
The study was limited by the small sample size and the short follow-up period.
Participant Demographics
Median age was 64 years, with 95% having an ECOG performance status of 0 or 1.
Statistical Information
P-Value
p>0.05
Confidence Interval
95% CI, 29.5–57.7%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website